Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 17;12(6):796.
doi: 10.3390/brainsci12060796.

Hypogonadism in Male Patients with Pituitary Adenoma and Its Related Mechanism: A Review of Literature

Zisheng Yan  1 , Ting Lei  1
Affiliations
Review

Hypogonadism in Male Patients with Pituitary Adenoma and Its Related Mechanism: A Review of Literature

Zisheng Yan et al. Brain Sci. .

Abstract

Maintaining normal gonadal axis hormone levels is important for improving the condition of male patients with pituitary adenoma. The current literature is somewhat divided on the results of evaluations of gonadal axis function in male patients with pituitary adenoma before and after treatment, and the increasing demand for better quality of life has provided motivation for this research to continue. In this article, we summarize the feasibility of using testosterone as an indicator for assessing male function and discuss the changes reported in various studies for gonadal hormones before and after treatment in male patients with pituitary adenoma. It is important for clinicians to understand the advantages of each treatment option and the effectiveness of assessing gonadal function. The rationale behind the theory that pituitary adenomas affect gonadal function and the criteria for evaluating pituitary-gonadal axis hormones should be explored in more depth.

Keywords: hypogonadism; hypothalamic–pituitary–gonadal axis; pituitary adenoma; testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment in

References

    1. Ezzat S., Asa S.L., Couldwell W.T., Barr C.E., Dodge W.E., Vance M.L., McCutcheon I.E. The prevalence of pituitary adenomas: A systematic review. Cancer. 2004;101:613–619. doi: 10.1002/cncr.20412. - DOI - PubMed
    1. Dolecek T.A., Propp J.M., Stroup N.E., Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro. Oncol. 2012;14:v1–v49. doi: 10.1093/neuonc/nos218. - DOI - PMC - PubMed
    1. Asa S.L., Ezzat S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 2009;4:97–126. doi: 10.1146/annurev.pathol.4.110807.092259. - DOI - PubMed
    1. Scheithauer B.W., Gaffey T.A., Lloyd R.V., Sebo T.J., Kovacs K.T., Horvath E., Yapicier O., Young W.F., Jr., Meyer F.B., Kuroki T., et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59:341–353. doi: 10.1227/01.NEU.0000223437.51435.6E. - DOI - PubMed
    1. Suojun Z., Feng W., Dongsheng G., Ting L. Targeting Raf/MEK/ERK pathway in pituitary adenomas. Eur. J. Cancer. 2012;48:389–395. doi: 10.1016/j.ejca.2011.11.002. - DOI - PubMed

LinkOut - more resources